Tweak favors phosphate-induced calcification of vascular smooth muscle cells through canonical and non-canonical activation of NFκB

Cell Death and Disease

Volumn 7, Issue 7, 2016, Pages

  Henaut L ^a   Sanz, A B ^a,b   Martin Sanchez, D ^a   Carrasco, S ^a   Villa Bellosta, R ^a   Aldamiz Echevarria, G ^a   Massy, Z A ^c,d   Sanchez Nino, M D ^a,b   Ortiz, A ^a,b,e  

^a UNIVERSIDAD AUTÓNOMA DE MADRID   (Spain)

^b REDINREN   (Spain)

^c HÔPITAL AMBROISE PARÉ   (France)

^d CENTRE FOR RESEARCH IN EPIDEMIOLOGY AND POPULATION HEALTH   (France)

^e Section of Nephrology   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

ALKALINE PHOSPHATASE; BONE MORPHOGENETIC PROTEIN 2; GELATINASE B; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; MESSENGER RNA; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; SMALL INTERFERING RNA; TUMOR NECROSIS FACTOR; ACTA2 PROTEIN, HUMAN; ACTIN; ALPL PROTEIN, HUMAN; BMP2 PROTEIN, HUMAN; MAPK1 PROTEIN, HUMAN; MMP9 PROTEIN, HUMAN; MYH11 PROTEIN, HUMAN; MYOSIN HEAVY CHAIN; PHOSPHATE; PROTEIN BINDING; RELB PROTEIN, HUMAN; TNFSF12 PROTEIN, HUMAN; TRANSCRIPTION FACTOR RELB; TUMOR NECROSIS FACTOR RECEPTOR; TWEAK RECEPTOR;

APOPTOSIS; ARTICLE; BLOOD VESSEL CALCIFICATION; CONFOCAL MICROSCOPY; CONTROLLED STUDY; CYTOKINE RELEASE; DOWN REGULATION; ENZYME ACTIVITY; ENZYME INHIBITION; ENZYME PHOSPHORYLATION; HUMAN; HUMAN CELL; IN VITRO STUDY; KIDNEY TUBULE CELL; PHENOTYPE; PRIORITY JOURNAL; TRANSACTIVATION; UPREGULATION; VASCULAR SMOOTH MUSCLE CELL; WESTERN BLOTTING; ANTAGONISTS AND INHIBITORS; DRUG EFFECTS; GENE EXPRESSION REGULATION; GENETICS; METABOLISM; PATHOLOGY; PRIMARY CELL CULTURE; SIGNAL TRANSDUCTION; SMOOTH MUSCLE CELL; VASCULAR SMOOTH MUSCLE;

ACTINS; ALKALINE PHOSPHATASE; BONE MORPHOGENETIC PROTEIN 2; GENE EXPRESSION REGULATION; HUMANS; MATRIX METALLOPROTEINASE 9; MITOGEN-ACTIVATED PROTEIN KINASE 1; MITOGEN-ACTIVATED PROTEIN KINASE 3; MUSCLE, SMOOTH, VASCULAR; MYOCYTES, SMOOTH MUSCLE; MYOSIN HEAVY CHAINS; PHOSPHATES; PRIMARY CELL CULTURE; PROTEIN BINDING; RECEPTORS, TUMOR NECROSIS FACTOR; RNA, MESSENGER; RNA, SMALL INTERFERING; SIGNAL TRANSDUCTION; TRANSCRIPTION FACTOR RELB; TUMOR NECROSIS FACTORS; VASCULAR CALCIFICATION;

EID: 85000874000     PISSN: None     EISSN: 20414889     Source Type: Journal    
DOI: 10.1038/cddis.2016.220     Document Type: Article

References (60)

1. Rennenberg RJ, Kessels AG, Schurgers LJ, van Engelshoven JM, de Leeuw PW, Kroon AA. Vascular calcifications as a marker of increased cardiovascular risk: a meta-analysis. Vasc Health Risk Manag 2009; 5: 185–197.
2. Massy ZA, Drüeke TB. Vascular calcification. Curr Opin Nephrol Hypertens 2013; 22: 405–412.
3. Shanahan CM, Crouthamel MH, Kapustin A, Giachelli CM. Arterial calcification in chronic kidney disease: key roles for calcium and phosphate. Circ Res 2011; 109: 697–711.
4. Brüünsgaard H, Pedersen BK. Age-related inflammatory cytokines and disease. Immunol Allergy Clin North Am 2003; 23: 15–39.
5. Kaysen GA. The microinflammatory state in uremia: causes and potential consequences. J Am Soc Nephrol 2001; 12: 1549–1557.
6. Bessueille L, Magne D. Inflammation: a culprit for vascular calcification in atherosclerosis and diabetes. Cell Mol Life Sci 2015; 72: 2475–2489.
7. Hénaut L, Sanchez-Nino MD, Aldamiz-Echevarría Castillo G, Sanz AB, Ortiz A. Targeting local vascular and systemic consequences of inflammation on vascular and cardiac valve calcification. Expert Opin Ther Targets 2016; 20: 89–105.
8. Blanco-Colio LM. TWEAK/Fn14 axis: a promising target for the treatment of cardiovascular diseases. Front Immunol 2014; 5: 3.
9. Chicheportiche Y, Bourdon PR, Xu H, Hsu YM, Scott H, Hession C et al. TWEAK, a new secreted ligand in the tumor necrosis factor family that weakly induces apoptosis. J Biol Chem 1997; 272: 32401–32410.
10. Sanz AB, Sanchez-Niño MD, Izquierdo MC, Jakubowski A, Justo P, Blanco-Colio LM et al. Tweak induces proliferation in renal tubular epithelium: a role in uninephrectomy induced renal hyperplasia. J Cell Mol Med 2009; 13: 3329–3342.
11. Yoriki R, Akashi S, Sho M, Nomi T, Yamato I, Hotta K et al. Therapeutic potential of the TWEAK/Fn14 pathway in intractable gastrointestinal cancer. Exp Ther Med 2011; 2: 103–108.
12. Sanz AB, Justo P, Sanchez-Niño MD, Blanco-Colio LM, Winkles JA, Kreztler M et al. The cytokine TWEAK modulates renal tubulointerstitial inflammation. J Am Soc Nephrol 2008; 19: 695–703.
13. Ucero AC, Benito-Martin A, Fuentes-Calvo I, Santamaria B, Blanco J, Lopez-Novoa JM et al. TNF-related weak inducer of apoptosis (TWEAK) promotes kidney fibrosis and Ras-dependent proliferation of cultured renal fibroblast. Biochim Biophys Acta 2013; 1832: 1744–1755.
14. Muñoz-García B, Martín-Ventura JL, Martínez E, Sánchez S, Hernández G, Ortega L et al. Fn14 is upregulated in cytokine-stimulated vascular smooth muscle cells and is expressed in human carotid atherosclerotic plaques: modulation by atorvastatin. Stroke 2006; 37: 2044–2053.
15. Burkly LC, Michaelson JS, Hahm K, Jakubowski A, Zheng TS. TWEAKing tissue remodeling by a multifunctional cytokine: role of TWEAK/Fn14 pathway in health and disease. Cytokine 2007; 40: 1–16.
16. Martín-Ventura JL, Lindholt JS, Moreno JA, Vega de Céniga M, Meilhac O, Michel JB et al. Soluble TWEAK plasma levels predict expansion of human abdominal aortic aneurysms. Atherosclerosis 2011; 214: 486–489.
17. Tarín C, Fernández-Laso V, Sastre C, Madrigal-Matute J, Gómez M, Zaragoza C et al. Tumor necrosis factor-like weak inducer of apoptosis or Fn14 deficiency reduce elastase perfusion-induced aortic abdominal aneurysm in mice. J Am Heart Assoc 2014; 3: e000723.
18. Sastre C, Fernández-Laso V, Madrigal-Matute J, Muñoz-García B, Moreno JA, Pastor-Vargas C et al. Genetic deletion or TWEAK blocking antibody administration reduce atherosclerosis and enhance plaque stability in mice. J Cell Mol Med 2014; 18: 721–734.
19. Buchet R, Millán JL, Magne D. Multisystemic functions of alkaline phosphatases. Methods Mol Biol 2013; 1053: 27–51.
20. Sanz AB, Sanchez-Niño MD, Izquierdo MC, Jakubowski A, Justo P, Blanco-Colio LM et al. TWEAK activates the non-canonical NFkappaB pathway in murine renal tubular cells: modulation of CCL21. PLoS One 2010; 5: e8955.
21. Moreno JA, Sastre C, Madrigal-Matute J, Muñoz-García B, Ortega L, Burkly LC et al. HMGB1 expression and secretion are increased via TWEAK-Fn14 interaction in atherosclerotic plaques and cultured monocytes. Arterioscler Thromb Vasc Biol 2013; 33: 612–620.
22. Moreno PR, Fuster V. New aspects in the pathogenesis of diabetic atherothrombosis. J Am Coll Cardiol 2004; 44: 2293–2300.
23. Donath MY, Böni-Schnetzler M, Ellingsgaard H, Halban PA, Ehses JA. Cytokine production by islets in health and diabetes: cellular origin, regulation and function. Trends Endocrinol Metab 2010; 21: 261–267.
24. Jean G, Bresson E, Terrat JC, Vanel T, Hurot JM, Lorriaux C et al. Peripheral vascular calcification in long-haemodialysis patients: associated factors and survival consequences. Nephrol Dial Transplant 2009; 24: 948–955.
25. Ortiz A, Sanz AB, Muñoz García B, Moreno JA, Sánchez Niño MD, Martín-Ventura JL et al. Considering TWEAK as a target for therapy in renal and vascular injury. Cytokine Growth Factor Rev 2009; 20: 251–258.
26. Sanz AB, Izquierdo MC, Sanchez-Niño MD, Ucero AC, Egido J, Ruiz-Ortega M et al. TWEAK and the progression of renal disease: clinical translation. Nephrol Dial Transplant 2014; 29(Suppl 1): i54–i62.
27. Ruiz-Ortega M, Ortiz A, Ramos AM. Tumor necrosis factor-like weak inducer of apoptosis (TWEAK) and kidney disease. Curr Opin Nephrol Hypertens 2014; 23: 93–100.
28. Jelić-Ivanović Z, Bujisić N, Spasić S, Bogavac-Stanojević N, Spasojević-Kalimanovska V, Kotur-Stevuljević J. Circulating sTWEAK improves the prediction of coronary artery disease. Clin Biochem 2009; 42: 1381–1386.
29. Chorianopoulos E, Rosenberg M, Zugck C, Wolf J, Katus HA, Frey N. Decreased soluble TWEAK levels predict an adverse prognosis in patients with chronic stable heart failure. Eur J Heart Fail 2009; 11: 1050–1056.
30. Moreno JA, Dejouvencel T, Labreuche J, Smadja DM, Dussiot M, Martin-Ventura JL et al. Peripheral artery disease is associated with a high CD163/TWEAK plasma ratio. Arterioscler Thromb Vasc Biol 2010; 30: 1253–1262.
31. Blanco-Colio LM, Martín-Ventura JL, Muñóz-García B, Orbe J, Páramo JA, Michel JB et al. Identification of soluble tumor necrosis factor-like weak inducer of apoptosis (sTWEAK) as a possible biomarker of subclinical atherosclerosis. Arterioscler Thromb Vasc Biol 2007; 27: 916–922.
32. Kralisch S, Ziegelmeier M, Bachmann A, Seeger J, Lössner U, Blüher M et al. Serum levels of the atherosclerosis biomarker sTWEAK are decreased in type 2 diabetes and end-stage renal disease. Atherosclerosis 2008; 199: 440–444.
33. Gungor O, Kircelli F, Asci G, Carrero JJ, Tatar E, Demirci MS et al. Soluble TWEAK level: is it a marker for cardiovascular disease in long-term hemodialysis patients? J Nephrol 2013; 26: 136–143.
34. Carrero JJ, Ortiz A, Qureshi AR, Martín-Ventura JL, Bárány P, Heimbürger O et al. Additive effects of soluble TWEAK and inflammation on mortality in hemodialysis patients. Clin J Am Soc Nephrol 2009; 4: 110–118.
35. Bobryshev YV, Orekhov AN, Sobenin I, Chistiakov DA. Role of bone-type tissue-nonspecific alkaline phosphatase and PHOSPO1 in vascular calcification. Curr Pharm Des 2014; 20: 5821–5828.
36. Villa-Bellosta R, Levi M, Sorribas V. Vascular smooth muscle cell calcification and SLC20 inorganic phosphate transporters: effects of PDGF, TNF-alpha, and Pi. Pflugers Arch 2009; 458: 1151–1161.
37. Martín P, Mora I, Cortes MA, Calleros L, García-Jerez A, Ortiz A et al. Relevant role of PKG in the progression of fibrosis induced by TNF-like weak inducer of apoptosis. Am J Physiol Renal Physiol 2014; 307: F75–F85.
38. Brown SA, Richards CM, Hanscom HN, Feng SL, Winkles JA. The Fn14 cytoplasmic tail binds tumour-necrosis-factor-receptor-associated factors 1, 2, 3 and 5 and mediates nuclear factor-kappaB activation. Biochem J 2003; 371: 395–403.
39. Saitoh T, Nakayama M, Nakano H, Yagita H, Yamamoto N, Yamaoka S. TWEAK induces NF-kappaB2 p100 processing and long lasting NF-kappaB activation. J Biol Chem 2003; 278: 36005–36012.
40. Masuda M, Miyazaki-Anzai S, Levi M, Ting TC, Miyazaki M. PERK-eIF2α-ATF4-CHOP signaling contributes to TNFα-induced vascular calcification. J Am Heart Assoc 2013; 2: e000238.
41. Zhao G, Xu MJ, Zhao MM, Dai XY, Kong W, Wilson GM et al. Activation of nuclear factor-kappa B accelerates vascular calcification by inhibiting ankylosis protein homolog expression. Kidney Int 2012; 82: 34–44.
42. Poveda J, Tabara LC, Fernandez-Fernandez B, Martin-Cleary C, Sanz AB, Selgas R et al. TWEAK/Fn14 and non-canonical NF-kappaB signaling in kidney disease. Front Immunol 2013; 4: 447.
43. Al-Aly Z, Shao JS, Lai CF, Huang E, Cai J, Behrmann A et al. Aortic Msx2-Wnt calcification cascade is regulated by TNF-alpha-dependent signals in diabetic Ldlr-/-mice. Arterioscler Thromb Vasc Biol 2007; 27: 2589–2596.
44. Tintut Y, Patel J, Parhami F, Demer LL. Tumor necrosis factor-alpha promotes in vitro calcification of vascular cells via the cAMP pathway. Circulation 2000; 102: 2636–2642.
45. Lee HL, Woo KM, Ryoo HM, Baek JH. Tumor necrosis factor-alpha increases alkaline phosphatase expression in vascular smooth muscle cells via MSX2 induction. Biochem Biophys Res Commun 2010; 391: 1087–1092.
46. Lencel P, Delplace S, Pilet P, Leterme D, Miellot F, Sourice S et al. Cell-specific effects of TNF-α and IL-1β on alkaline phosphatase: implication for syndesmophyte formation and vascular calcification. Lab Invest 2011; 91: 1434–1442.
47. Son BK, Akishita M, Iijima K, Kozaki K, Maemura K, Eto M et al. Adiponectin antagonizes stimulatory effect of tumor necrosis factor-alpha on vascular smooth muscle cell calcification: regulation of growth arrest-specific gene 6-mediated survival pathway by adenosine 5'-monophosphate-activated protein kinase. Endocrinology 2008; 149: 1646–1653.
48. Rucker RB. Calcium binding to elastin. Adv Exp Med Biol 1974; 48: 185–209.
49. Basalyga DM, Simionescu DT, Xiong W, Baxter BT, Starcher BC, Vyavahare NR. Elastin degradation and calcification in an abdominal aorta injury model: role of matrix metalloproteinases. Circulation 2004; 110: 3480–3487.
50. Cao Q, Jiang Y, Shi J, Xu C, Liu X, Yang T et al. Artemisinin inhibits the proliferation, migration, and inflammatory reaction induced by tumor necrosis factor-α in vascular smooth muscle cells through nuclear factor kappa B pathway. J Surg Res 2015; 194: 667–678.
51. Kaden JJ, Dempfle CE, Grobholz R, Tran HT, Kiliç R, Sarikoç A et al. Interleukin-1 beta promotes matrix metalloproteinase expression and cell proliferation in calcific aortic valve stenosis. Atherosclerosis 2003; 170: 205–211.
52. Mustonen E, Säkkinen H, Tokola H, Isopoussu E, Aro J, Leskinen H et al. Tumour necrosis factor-like weak inducer of apoptosis (TWEAK) and its receptor Fn14 during cardiac remodelling in rats. Acta Physiol (Oxf) 2010; 199: 11–22.
53. Wiley SR, Cassiano L, Lofton T, Davis-Smith T, Winkles JA, Lindner V et al. A novel TNF receptor family member binds TWEAK and is implicated in angiogenesis. Immunity 2001; 15: 837–846.
54. Donohue PJ, Richards CM, Brown SA, Hanscom HN, Buschman J, Thangada S et al. and Winkles JA. TWEAK is an endothelial cell growth and chemotactic factor that also potentiates FGF-2 and VEGF-A mitogenic activity. Arterioscler Thromb Vasc Biol 2003; 23: 594–600.
55. Chorianopoulos E, Heger T, Lutz M, Frank D, Bea F, Katus HA et al. FGF-inducible 14-kDa protein (Fn14) is regulated via the RhoA/ROCK kinase pathway in cardiomyocytes and mediates nuclear factor-kappaB activation by TWEAK. Basic Res Cardiol 2010; 105: 301–313.
56. Muñoz-García B, Moreno JA, López-Franco O, Sanz AB, Martín-Ventura JL, Blanco J et al. Tumor necrosis factor-like weak inducer of apoptosis (TWEAK) enhances vascular and renal damage induced by hyperlipidemic diet in ApoE-knockout mice. Arterioscler Thromb Vasc Biol 2009; 29: 2061–2068.
57. Wang Y, Shan J, Yang W, Zheng H, Xue S. High mobility group box 1 (HMGB1) mediates high-glucose-induced calcification in vascular smooth muscle cells of saphenous veins. Inflammation 2013; 36: 1592–1604.
58. Moreno JA, Izquierdo MC, Sanchez-Niño MD, Suárez-Alvarez B, Lopez-Larrea C, Jakubowski A et al. The inflammatory cytokines TWEAK and TNFα reduce renal klotho expression through NFκB. J Am Soc Nephrol 2011; 22: 1315–1325.
59. Hénaut L, Boudot C, Massy ZA, Lopez-Fernandez I, Dupont S, Mary A et al. Calcimimetics increase CaSR expression and reduce mineralization in vascular smooth muscle cells: mechanisms of action. Cardiovasc Res 2014; 101: 256–265.
60. Villa-Bellosta R, Rivera-Torres J, Osorio FG, Acín-Pérez R, Enriquez JA, López-Otín C et al. Defective extracellular pyrophosphate metabolism promotes vascular calcification in a mouse model of Hutchinson-Gilford progeria syndrome that is ameliorated on pyrophosphate treatment. Circulation 2013; 127: 2442–2451.